IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

Arun has over 15 years’ experience covering the Technology sector. During this time, he has worked with technology start-ups and as an equity analyst in investment banks and independent research firms. He was formerly a Technology Analyst for Canaccord Genuity, Altium Securities, Espirito Santo Investment Bank, Noble Group and Clear Capital. He has a dual Master’s degree in Financial Engineering and Industrial and Operations Engineering from the University of Michigan. He obtained his Bachelor’s degree in Mechanical Engineering from the Indian Institute of Technology, Bombay. He is also a CFA charterholder.

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Equity Capital Markets

<p><a href="https://www.smartkarma.com/entities/jw-therapeutics" target="_blank" data-smartkarma-citation="entities:29679:1" rel="noopener">JW Therapeutics (2126 HK)</a> was founded in 2016 by Juno, a <a href="https://www.smartkarma.com/entities/bristol-myers-squibb-co" target="_blank" data-smartkarma-citation="entities:1133:1" rel="noopener">Bristol Myers Squibb Co (BMY US)</a> company, and <a href="https://www.smartkarma.com/entities/wuxi-apptec-co-ltd-bf4a1265-beef-48b6-b82d-29308426030f" target="_blank" data-smartkarma-citation="entities:27795:1" rel="noopener">WuXi AppTec Co. Ltd. (2359 HK)</a>. JW has built an integrated platform focused on developing, manufacturing and commercializing breakthrough cell-based immunotherapies for haematological cancers and solid tumours. JW has launched a Hong Kong IPO to raise net proceeds of HK$2,017.6 million ($260 million) at the mid-point of the IPO price range.</p><div class="content-highlight"><p>JW’s core drug candidate’s competitive advantage in the CAR-T market in China is supported by its potential best-in-class safety profile with competitive efficacy, physicians’ familiarity due to a large number of clinical sites in China and manufacturing quality. Overall, we believe that the prospectus JW’s core drug asset is favourable. </p></div>

JW Therapeutics (2126 HK) was founded in 2016 by Juno, a Bristol Myers Squibb Co (BMY US) company, and WuXi AppTec Co. Ltd. (2359 HK). JW has built an integrated platform focused on developing, manufacturing and commercializing breakthrough cell-based immunotherapies for haematological cancers and solid tumours. JW has launched a Hong Kong IPO to raise net proceeds of HK$2,017.6 million ($260 million) at the mid-point of the IPO price range.JW’s core drug candidate’s competitive advantage in the CAR-T market in China is supported by its potential best-in-class safety profile with competitive efficacy, physicians’ familiarity due to a large number of clinical sites in China and manufacturing quality. Overall, we believe that the prospectus JW’s core drug asset is favourable. 

JW Therapeutics IPO Initiation: Potent Medicine